Although the policies are frequent，But to solve the & ldquo; shortage & rdquo;。The reporter learned from the data of the Health Industry Research Institute，Among thousands of pharmaceutical factories in China，less than 20%of manufacturers involved in producing children's medicines，Among them, there are less than 20 manufacturers specializing in children's medication，0.1%of the total number of pharmaceutical plants，Including Rukangzhi Pharmaceutical、Sunflower Pharmaceutical、Dain Pharmaceutical and Wang Laoji Pharmaceutical，All are specifically produced or involved in children's medicine。

 

  To welcome & ldquo; Children's medicine & rdquo; blue ocean，Related pharmaceutical companies have made responses this year。For example, May 27 this year，Sunflower Pharmaceutical announced that it will invest 50 million yuan to set up Sunflower Pharmaceutical Group Xiao Sunflower Health Technology Co., Ltd.，Independent operation of the market stake online sports bettingstake online sports bettingof focusing on children's medicine。and on March 24，Kangzhi Pharmaceutical announced through future development plan，Deep cultivation of children's medicine market。early March，Wang Laoji Pharmaceutical also said that this year will pass the & ldquo; three dolls & rdquo;。

 

  But currently in the domestic children's medicine market，The problem of a single product variety and the concentration of the R & D field still exists，That is, children's medicine is still concentrated in a cold、Frequent diseases such as fever and cough。​​Using children's medicine brands & ldquo; Little sunflower & rdquo;，Data shows that the company's children's medicines include cold medicine、Anti -fever medicine、Cough medicine、Gastrointestinals, etc.。

 

  Similar situations also exist in Kangzhi Pharmaceutical, which focuses on producing children's medicines，The company’s children's medicine products are also concentrated in heating、Cold、diarrhea digestion、Phlegm、Anti -infection and children's supplements and other fields。

 

  For some pharmaceutical companies，Children's medicine is not high。Reporter found it in the 2015 annual report of Kangzhi Pharmaceutical，Its operating income last year compared with 2014，Dedicated declines except children's supplements products，If operating income accounts for relatively large heating series products、Cold series products and cough and phlegm series products，Business income decreased by 58.85%compared with last year、27.36%and 46.07%; and in terms of gross profit margin，The reporter found that in addition to the increase in the revenue of the cold series of products increased by 4.54%，Anti -heating series products and cough and phlegm series products decreased by 0.57%and 5.46%, respectively。

 

  Stake Sports Bettingstake sports betting appReporter found in the annual report，The adult pharmaceutical business of Kangzhi Pharmaceutical has increased significantly increasing revenue，Although the gross profit margin of the company's adult medicine last year decreased by 0.80%compared to 2014，But in terms of operating income，Adult drug revenue accounted for the company's total revenue proportion increased from 34.73%in 2014 to 65.38%last year，increased by 88.82%year -on -year。In other words, the company's operating income last year was more from adult medicine。

 

  Of course，There are also enterprises expanding in other areas of children's medicine。Take Daidin Pharmaceutical as an example，The company is mainly concentrated in the production of vitamin AD supplements of infants and young children、R & D and sales。According to the research report of the South China Securities，The company's infant vitamin AD supplementary products have occupied 60%of the market share，Become the most direct and biggest beneficiary of the two -child policy & rdquo;。

 

  Experts analyze and develop new varieties of children's medicines.

 

  Although the existing policy encourages the variety of children's medicines to expand，But for enterprises，Entering the field of children's medicines is continuous & ldquo; deep cultivation & rdquo; existing varieties，Still & ldquo; Response call & rdquo; open up new disease products，This has also caused some discussions in the industry。

 

  Support & ldquo; Deep plowing & rdquo; The existing market person thinks，Cold、fever and diarrhea are almost & ldquo; 100 % & rdquo;，In terms of market volume, it is far greater than other diseases; and like cardiovascular、Endocrine, etc.，Children's onset is mostly caused by genetic factors，It may be found in the fetal stage with genetic testing technology; stake online sports bettingin addition, like children'Stake Sports Bettingstake sports betting apps rare diseases，Due to the high factor of drug research and development, high investment cost，Market returns may not meet expectations。

 

  Some opinion thinks，Open up a new disease field，In fact，Relatively low input cost，This can be supported by national policy，It is also a way that is relatively willing to move forward。

 

  but，Some people in the industry said，Whether it is developing existing varieties or pioneering new varieties，Children's medicine development actually fell into & ldquo; dilemma & rdquo; situation。Shi Lichen, the person in charge of Beijing Dingchen Medical Consulting Center, said，From the perspective of existing children's medicines，The market is actually caught in the saturation stage。& ldquo; Although some departments have issued documents this year to regulate the administration habits of pediatricians，But it has not played a role。Under the habit of inherent medicine，These common diseases of these children are often facing the competition of adult medicines。& rdquo;

 

  Shi Lichen thinks，Actually existing & ldquo; Children's medicine market & rdquo;，One of the reasons is that the doctor & ldquo; the irregularity of the doctor's medication halves halved & rdquo;，This is equivalent to let the existing children's medicines go to & ldquo; grab the market & rdquo; another reason is that the existing bidding system does not take further preferential measures for children's medicine，& ldquo; If these two points are not solved at the national level，The children's drug market is unable to talk about & rdquo;。

 

  For new varieties of children's medicines，Shi Lichen believes that the policy is going on for a long time，The reason is that there is no large -scale children's disease spectrum at present。For manufacturers，Which is stake sports betting appthe disease of children's high incidence，Which stake betting appchildren's disease drug gap is large，Disease spectrum is required as a reference analysis，and comprehensively evaluate the cost of R & D cost。& ldquo; And in addition to reference disease spectrum，The research and development cycle of new children's new drugs is also at least two years longer than ordinary medicines，This is not simple & lsquo; reduces dosage & rsquo;，It also needs to conduct clinical trials for children，Evaluation and reporting drugs to children's various reactions，can be put into production and sales，Therefore, with the support of authoritative data at present，New varieties of pioneering children's medicine are difficult。& rdquo; Shi Lichen said。